Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5389053 | 0.84 | MEN1 (0.40) | MITFMEN1KMT2ATSHRCYP1A2 | |
| SCHEMBL5396632 | 0.78 | MPO (0.36) | MPOBACE1BACE2ALDH1A1HSD11B1 | |
| SCHEMBL5396081 | 0.76 | MITF (0.34) | MITFMEN1KMT2AHSD11B1 | |
| SCHEMBL3123580 | 0.72 | — | — | |
| SCHEMBL7073909 | 0.71 | — | — | |
| SCHEMBL5396638 | 0.68 | ALDH1A1 (0.34) | MEN1KMT2ATSHRCYP1A2CYP2C19 | |
| SCHEMBL576540 | 0.67 | BRD4 (0.41) | MEN1KMT2ACYP1A2TDP1ALDH1A1 | |
| SCHEMBL6304953 | 0.66 | CHRNB2 (0.36) | MEN1KMT2ATSHRCYP1A2LMNA | |
| SCHEMBL5410307 | 0.66 | MPO (0.30) | MPO | |
| SCHEMBL19923592 | 0.66 | MITF (0.42) | MITFMEN1KMT2ATSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297819-B2 | Open-chain alkoxyamines and their corresponding nitroxides for controlled low temperature radical polymerization | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1481012-B1 | OPEN-CHAIN ALKOXYAMINES AND THEIR CORRESPONDING NITROXIDES FOR CONTROLLED LOW TEMPERATURE RADICAL POLYMERIZATION | CIBA SC HOLDING AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050124814-A1 | Open-chain alkoxyamines and their corresponding nitroxides for controlled low temperature radical polymerization | CIBA SPECIALTY CHEMICALS CORPORATION | 2005-06-09 | — | — | US | disclosed |
| EP-1481012-A1 | OPEN-CHAIN ALKOXYAMINES AND THEIR CORRESPONDING NITROXIDES FOR CONTROLLED LOW TEMPERATURE RADICAL POLYMERIZATION | Ciba SC Holding AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074572-A1 | OPEN-CHAIN ALKOXYAMINES AND THEIR CORRESPONDING NITROXIDES FOR CONTROLLED LOW TEMPERATURE RADICAL POLYMERIZATION | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124814-A1 | Open-chain alkoxyamines and their corresponding nitroxides for controlled low temperature radical polymerization | ALOX5, NOS2, NOS1 | MITF 4433/4885MEN1 4634/4885KMT2A 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.